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Abstract G protein-coupled receptor kinases (GRKs) phos-
phorylate agonist-occupied G protein-coupled receptors, leading
to receptor desensitization. Seven GRKs, designated GRK1
through 7, have been characterized. GRK5 is negatively
regulated by protein kinase C. We investigated whether human
substance P receptor (hSPR) is a substrate of GRK5. We report
that membrane-bound hSPR is phosphorylated by purified
GRK5, and that both the rate and extent of phosphorylation
increase dramatically in the presence of substance P. The
phosphorylation has a high stoichiometry (20, 4 mol phosphate/
mol hSPR) and a low Km (1.7 , 0.1 nM). These data provide the
first evidence that hSPR is a substrate of GRK5. 0 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
A wide array of physiological functions (vision, smell, taste,
heart rate, neurotransmission, and cell proliferation) are regu-
lated through the actions of G protein-coupled receptors
(GPCRs) [1]. Stimulation of GPCRs by speci¢c agonists not
only transmits signals to G proteins and e¡ectors but also
modi¢es GPCR function by means of desensitization, seques-
tration, internalization, and down-regulation. According to
current models, agonist-dependent phosphorylation of
GPCRs plays a key role in receptor desensitization [2,3].
The agonist-dependent phosphorylation of a GPCR can be
catalyzed both by second messenger-activated protein kinases,
such as protein kinase A (PKA) or protein kinase C (PKC),
and by members of the G protein-coupled receptor kinase
(GRK) family. GRK-catalyzed phosphorylation of GPCRs
facilitates binding of arrestins, which disrupt receptor/G pro-
tein coupling resulting in a loss of GPCR signaling [2,3]. Since
GRKs mediate agonist-dependent phosphorylation of
GPCRs, they represent an important family of enzymes in
the regulation of cell signaling.
Seven distinct GRKs, termed GRK1 through GRK7, have
been identi¢ed to date [4^7] ; these isozymes di¡er in their
tissue distribution, mechanism of association with the plasma
membrane, and autophosphorylation [4,5,8,9]. Di¡erences
have also been reported in the regulation of GRKs by PKC
and the calcium binding protein, calmodulin [5,9]. Calmodulin
strongly inhibits GRK5 but only weakly inhibits GRK2. Also,
PKC-catalyzed phosphorylation of GRK2 and GRK5 causes
the opposite e¡ects: GRK2 activity increases while GRK5
activity decreases [5]. This regulation of GRK activity is of
particular importance in determining cellular responses. For
example, since a decrease in GRK5 activity was observed after
phosphorylation by PKC, GRK5 was not expected to regulate
phospholipase C (PLC)-coupled receptors because stimulation
of these receptors activates PKC [10].
While our understanding of the biology of various GRKs
has grown considerably, the substrate speci¢city of most
GRKs remains poorly de¢ned [4], because the native expres-
sion level of their substrates, GPCRs, is quite low. To date,
only a few GPCRs have been directly tested as GRK sub-
strates. This situation should change soon, however, because
many cloned GPCRs are being expressed at high levels in Sf9
insect cells using the baculovirus expression system [11]. Pre-
viously we reported a high level of expression of human sub-
stance P receptor (hSPR) in Sf9 cells and have demonstrated
that hSPR in urea-washed membranes is e⁄ciently phosphor-
ylated by GRK2 [12,13]. Consistent with these in vitro ¢nd-
ings, we have also found that hSPR stimulation leads to the
rapid translocation of GRK2 from the cytosol to the plasma
membrane of live cells [14]. In the present study we tested
whether hSPR is a substrate of GRK5 using an in vitro ap-
proach. We show that hSPR in urea-washed Sf9 membranes
undergoes agonist-dependent phosphorylation by puri¢ed
GRK5. The phosphorylation of hSPR yields a high stoichi-
ometry and the reaction is characterized by a low Km. These
data suggest that GRK5 may play a role in hSPR function.
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2. Materials and methods
2.1. Materials
Aprotinin, bacitracin, chymostatin, leupeptin, phenylmethylsulfonyl
£uoride (PMSF), soybean trypsin inhibitor, calmodulin, heparin, and
substance P (SP) were from Sigma (St. Louis, MO, USA);
[3H]SR140333 (27.8 Ci/mmol) and [32P]Q-ATP (3000 Ci/mmol) were
from New England Nuclear (Boston, MA, USA). Graces insect cell
medium, gentamicin, and fetal bovine serum were from Gibco (Gai-
thersburg, MD, USA); Sf9 cells were from Invitrogen (Carlsbad, CA,
USA); diethylaminoethyl-Sephacel and heparin-Sepharose were from
Pharmacia (Piscataway, NJ, USA); bovine retinas were from Pel-
Freez (Rogers, AK, USA). The non-peptide SPR antagonist CP-
96345 was a gift from Dr. Saul Kadin, P¢zer Inc., Groton, CT,
USA. Anti-GRK5 antibody and a goat-anti-rabbit, horseradish per-
oxidase-conjugated antibody were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Southern Biotechnology Asso-
ciates Inc. (Birmingham, AL, USA) raised a rabbit antiserum,
directed against 15 amino acids at the C-terminus of hSPR
(KTMTESFSFSSNVLS); as previously reported, this hSPR antise-
rum is suitable for immunoblotting as well as receptor immunopre-
cipitation [12]. Chemiluminescence reagent (SuperSignal0) was ob-
tained from Pierce (Rockford, IL, USA). Urea-washed Sf9
membranes expressing hSPR were prepared as previously described
[12]. We used urea-washed Sf9 plasma membranes because, as we
showed previously, urea-washing increases the phosphorylation of
hSPR. Presumably this increase is due to the inactivation of ATP-
degrading ATPases in the non-urea-washed membranes [12]. Similar
to GRK2 [12], GRK5 also phosphorylated hSPR in non-urea-washed
plasma membranes (data not shown). The level of hSPR in urea-
washed Sf9 membranes was quantitated as previously described [13]
by ligand binding using [3H]SR140333. Urea-washed bovine rod outer
segment membranes were also prepared as previously described [12].
2.2. Isolation of human GRK5 cDNA and expression in Sf9 cells
The cDNA of GRK5 was isolated from a human heart cDNA
library by polymerase chain reaction using primers based on the pub-
lished sequence [15]. The GRK5 clone was veri¢ed by DNA sequenc-
ing, which revealed three di¡erences in the product relative to the
published sequence: position 1059 CsT, position 1062 CsA, and
position 1164 TsC. These base changes do not a¡ect the amino acid
sequence. GRK5 cDNA was cloned into the baculovirus transfer vec-
tor pVL1392 (Invitrogen, Carlsbad, CA, USA) and a high titer, re-
combinant baculovirus expressing GRK5 was prepared using the
BaculoGold0 transfection kit (PharMingen, San Diego, CA, USA).
The high titer, recombinant baculovirus was used to infect Sf9 insect
cells at a density of 2^2.5U106 cells/ml in spinner £asks. After 42^48 h
of incubation at 27‡C, cells were harvested and stored at 380‡C. The
maximal expression time for GRK5 was determined by immunoblot-
ting with GRK5-speci¢c antibody.
2.3. Puri¢cation of GRK5 expressed in Sf9 cells
Recombinant GRK5 was puri¢ed from Sf9 insect cell lysate follow-
ing a two-step procedure adapted from a previously published method
[16]. GRK5 was eluted ¢rst from an S-Sepharose column and then
from a heparin-Sepharose column, unlike Kunapuli et al. [16], in
which the second column was Mono-S. Unless otherwise noted, all
bu¡ers contained the following protease inhibitors: 1 mM benzami-
dine, 10 Wg/ml leupeptin, 5 Wg/ml aprotinin, 10 Wg/ml soybean trypsin
inhibitor, 1 Wg/ml pepstatin A, and 200 WM PMSF. Preparation of cell
lysates and subsequent elution from an S-Sepharose column were
similar to Kunapuli et al. [16]. Modi¢cations include absence of
0.02% Triton from the lysis bu¡er, centrifugation of lysate at
100 000Ug, equilibration of the S-Sepharose column with 300 mM
NaCl, and an elution gradient of 10 bed-volumes ranging from 300
to 800 mM NaCl at a £ow rate of 0.2 bed-volumes/min. Fractions
(2 ml) were collected and assayed for receptor kinase activity as pre-
viously described [12] using rhodopsin in urea-washed bovine rod
outer segments as a substrate. Elution fractions containing the
GRK5 activity were pooled and then applied to a 5 ml heparin-Seph-
arose column equilibrated with bu¡er A plus 250 mM NaCl. The
heparin column was washed with 10 column volumes of bu¡er A
plus 400 mM NaCl and eluted with a 100 ml linear NaCl gradient
from 400 mM to 1 M in bu¡er A containing 0.02% Triton X-100.
Fractions containing peak GRK5 activity (occurring at approximately
590^640 mM NaCl) were pooled, concentrated to approximately
500 Wl using a Centriprep-30 (Millipore, Bedford, MA, USA), and
then diluted 10-fold with bu¡er A plus 20 mM NaCl. The GRK5
preparation was then concentrated to approximately 600 Wl, glycerol
was added to a ¢nal concentration of 10%, and the enzyme was stored
at 380‡C. The purity of GRK5, as determined by silver staining, was
s 95%. No contamination by GRK2 was detectable on immunoblots
of up to 2.3 Wg of this preparation, nor was GRK2 detected in Sf9
plasma membrane preparations (data not shown).
Characteristics of the puri¢ed GRK5 matched those previously re-
ported for GRK5 [11,16]. Upon autophosphorylation, the GRK5 ap-
pears as a doublet with the faster-migrating (f) form converting to the
slower-migrating (s) form as autophosphorylation proceeds (Fig. 3);
this characteristic of GRK5 autophosphorylation has been described
[10]. In individual preparations the stoichiometry of GRK5 autophos-
phorylation ranged from 0.2 to 1.5 pmol phosphate/pmol GRK5.
Calmodulin/Ca2þ inhibits the GRK5-catalyzed phosphorylation of
rhodopsin with an IC50 of 200 nM, and stimulates GRK5 autophos-
phorylation as previously reported [17].
2.4. In vitro phosphorylation of hSPR with puri¢ed GRK5
Receptor phosphorylation assays were performed at 30‡C in a total
volume of 50 Wl containing 20 mM Tris^HCl (pH 7.4), 2 mM EDTA,
4 mM MgCl2, and 0.1 Wg of puri¢ed GRK5, plus di¡erent amounts of
Sf9 membrane proteins to vary the concentration of hSPR in the
reaction. Other components are noted in the ¢gure legends. Reactions
were started by adding 5 Wl of [32P]Q-ATP (1.0^1.3 mM; speci¢c ac-
tivity, 2^3 cpm/fmol) and stopped by adding 25 Wl of sodium dodecyl
sulfate (SDS) sample bu¡er (0.06 M Tris^HCl, pH 6.8, 2% SDS, 10%
glycerol, 0.025% bromophenol blue and 10% freshly added 2-mercap-
toethanol). Phosphorylated receptors were visualized by subjecting the
samples to 10% SDS^polyacrylamide gel electrophoresis (PAGE) fol-
lowed by autoradiography. The phosphorylated receptor bands were
excised from the dried gels, counted in a scintillation counter, and the
stoichiometry of phosphorylation was calculated from the amount of
receptor loaded onto the gel and the speci¢c activity of [32P]Q-ATP. As
we have reported previously [12], increasing the concentration of
hSPR reduces the stoichiometry of phosphorylation. Accordingly,
the hSPR concentration was held to a low level (W1 nM) for deter-
mining the phosphorylation stoichiometry. For kinetic studies, the
concentration of membrane-bound hSPR varied from 1 to 60 nM,
and initial rates were determined by stopping the reactions after
3 min; the reaction rate was linear up to 6 min at the lowest receptor
concentration (1 nM). The Km and Vmax values were obtained by a
non-linear ¢t of the data to the Michaelis^Menten equation using the
computer program, KaleidaGraph1 (Synergy Software, Reading, PA,
USA).
3. Results
3.1. Phosphorylation of hSPR in Sf9 membranes with puri¢ed
GRK5
Fig. 1 shows phosphorylation of hSPR in urea-washed Sf9
membranes by puri¢ed GRK5 in the absence or presence of
SPR ligands. As can be seen in Fig. 1 (lane 2), there is a
marked increase in the phosphorylation of a 45 kDa protein
upon addition of SP. Immunoprecipitation by hSPR-speci¢c
antiserum identi¢es the 45 kDa protein as phosphorylated
hSPR (data not shown). The SP-dependent phosphorylation
of hSPR by GRK5 is blocked by the SPR antagonist, CP-
96345 (Fig. 1, lane 3). These results indicate that hSPR phos-
phorylation by GRK5 is triggered by activation of hSPR
rather than occupancy of the ligand-binding site.
3.2. Characterization of GRK5-catalyzed phosphorylation of
SPR
The GRK5-catalyzed phosphorylation of hSPR is depen-
dent on the concentration of SP, and half-maximal phosphor-
ylation (EC50) occurs at 31R 2 nM SP (Fig. 2). This value
re£ects binding of SP to the low-a⁄nity state of hSPR [18],
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and is similar to the EC50 for SP-dependent phosphorylation
of hSPR by GRK2 [12].
Fig. 3 shows a time-course of GRK5-catalyzed phosphory-
lation of hSPR in the absence and presence of SP. In the
absence of SP, GRK5 phosphorylates hSPR slowly to a max-
imal stoichiometry of 4.0 R 0.8 mol phosphate/mol receptor,
which increases to 20R 4 mol phosphate/mol receptor follow-
ing stimulation with SP. The stoichiometry of GRK5-cata-
lyzed hSPR phosphorylation is comparable to the stoichiom-
etry of 19R 1 mol phosphate/mol receptor we reported
previously for GRK2-catalyzed phosphorylation of agonist-
occupied hSPR [12].
3.3. Kinetics of hSPR phosphorylation by GRK5
Fig. 4 shows initial rates of GRK5-catalyzed phosphoryla-
tion of agonist-occupied hSPR as a function of increasing
Fig. 1. GRK5-catalyzed phosphorylation of hSPR in urea-washed
Sf9 membranes. Receptor phosphorylation was performed in a 50 Wl
volume containing 70 fmol of hSPR in urea-washed Sf9 membranes
with a speci¢c activity of 140 pmol hSPR/mg protein, 30 nM GRK5,
0.12 mM [32P]Q-ATP (2^3 cpm/fmol), R 1 WM SP, R 500 WM SPR
antagonist CP-96,345, 20 mM Tris^HCl (pH 7.4), 2 mM EDTA,
and 4 mM MgCl2. Reactions proceeded for 60 min at 30‡C and
were stopped with 25 Wl SDS sample bu¡er, then analyzed by SDS^
PAGE/autoradiography. Background phosphorylation, without
GRK5 but with SP, was less than 1% (data not shown). The experi-
ment was repeated three times.
Fig. 2. E¡ect of increasing SP concentration on hSPR phosphoryla-
tion by GRK5. Phosphorylation reactions were performed in a 50
Wl volume containing 50 fmol hSPR in urea-washed Sf9 membranes
with a speci¢c activity of 100 pmol of hSPR/mg membrane protein,
30 nM GRK5, 0.12 mM [32P]Q-ATP (2^3 cpm/fmol), 20 mM Tris^
HCl (pH 7.4), 2 mM EDTA, and 4 mM MgCl2. The reaction pro-
ceeded for 60 min at 30‡C and was stopped by adding 25 Wl SDS
sample bu¡er, then analyzed by SDS^PAGE/autoradiography. The
experiment was repeated three times.
Fig. 3. Time-course of hSPR phosphorylation by GRK5 in urea-
washed Sf9 membranes. Phosphorylation reactions were performed
in a 50 Wl volume containing 70 fmol of hSPR in urea-washed
membranes with a speci¢c activity of 190 pmol of hSPR/mg protein,
30 nM GRK5, 1 WM SP, 0.12 mM [32P]Q-ATP (2^3 cpm/fmol),
20 mM Tris^HCl (pH 7.4), 2 mM EDTA, and 4 mM MgCl2. The
reaction mixtures were incubated at 30‡C for the indicated times,
stopped by adding 25 Wl of SDS sample bu¡er, and then analyzed
by SDS^PAGE/autoradiography. After autoradiography, the recep-
tor bands were excised, counted, and the stoichiometry of phosphor-
ylation was determined. The experiment was repeated twice.
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concentrations of membrane-bound hSPR. Analysis of these
data according to the Michaelis^Menten equation shows that
the reaction occurs with a Km of 1.7R 0.1 nM and a Vmax of
10R 3 nmol/min/mg (S.E.M. n=5). Under similar conditions,
rhodopsin is phosphorylated by GRK5 with a Km of 5 WM;
this is similar to the Km values of 2^16 WM reported by other
investigators [16,19] for GRK5-catalyzed rhodopsin phos-
phorylation. The Km of 1.7 nM for GRK5-catalyzed phos-
phorylation of hSPR is comparable to the Km of 3.6 nM
obtained for GRK2-catalyzed phosphorylation of hSPR in
the presence of GLQ [12].
4. Discussion
This study provides the ¢rst demonstration that hSPR
undergoes agonist-dependent phosphorylation catalyzed by
GRK5 in vitro. The GRK5-catalyzed phosphorylation of
hSPR occurs with a high stoichiometry (20 mol phosphate/
mol receptor) and a low Km (1.7 nM). These characteristics of
GRK5-catalyzed phosphorylation of hSPR are very similar to
the characteristics of in vitro phosphorylation of hSPR by
GRK2 [12]. Thus, hSPR is a good substrate of both GRK5
and GRK2. In the case of GRK2, the high a⁄nity observed
for hSPR in our in vitro studies was substantiated by the in
vivo data in which we demonstrated a sustained translocation
of GRK2 to plasma membrane upon activation of hSPR in
live cells [14]. Whether GRK5 exhibits high a⁄nity for hSPR
in vivo remains to be seen.
The main ¢nding of our study is that hSPR is e⁄ciently
phosphorylated by GRK5 in vitro. Previous in vitro studies
have tested the ability of GRK5 to phosphorylate GPCRs
that exert their actions through GKs (L2-adrenergic receptor
(AR)) or GKi (m2 muscarinic and K2C2-AR) pathways. These
studies found that GRK5 phosphorylates L2-AR e⁄ciently
[16,19] but phosphorylates m2-muscarinic and K2C2-ARs
poorly [20,21]. The present study extends these observations
by showing that GRK5 e⁄ciently phosphorylates hSPR,
which couples with Gq and stimulates PLC [22]. The ability
of GRK5 to phosphorylate hSPR is of interest because it has
been found previously that phosphorylation of GRK5 by
PKC causes a ¢ve-fold increase in the Km and a 2.8-fold
decrease in the Vmax of rhodopsin phosphorylation by
GRK5 [10]. Thus GRK5 would not be predicted to act on
the PLC-coupled receptor. Consistent with this expectation,
GRK5 does not signi¢cantly increase agonist-dependent phos-
phorylation of either the angiotensin II type 1 receptor [23] or
the K1b-AR [24], both of which stimulate PLC. Furthermore,
transgenic mice over-expressing GRK5 have been found to
have a marked desensitization of L-adrenergic response, but
the contractile response to angiotensin II, which functions
through Gq-coupled angiotensin receptors, remains un-
changed [25]. Clearly, these ¢ndings do not indicate any in-
teraction between GRK5 and PLC-coupled GPCRs. How-
ever, more recent evidence supports a signi¢cant role for
GRK5 in the regulation of PLC-coupled receptors such as
angiotensin II type 1A [26], metabotropic glutamate receptor
1A [27], V1-vasopressin receptor [28], and thrombin receptor
[29]. Furthermore, recent data from hybrid transgenic mice
over-expressing a constitutively active mutant of K1b-AR
and GRK5 indicate GRK5 is similarly involved in the regu-
lation of K1b-AR [30]. These data, taken together with our
demonstration of a high a⁄nity interaction between GRK5
and hSPR, support the notion that GRK5 can regulate the
function of PLC-coupled receptors.
Our results indicate that GRK5, like GRK2 [12], phosphor-
ylates hSPR to a high stoichiometry. Thus, it is likely that the
majority of hSPR’s 26 C-terminal serine/threonine residues
and 12 serine/threonine residues on the intracellular loops
become phosphorylated by GRK2 and GRK5. In this respect,
hSPR is like L2-AR which also undergoes robust phosphory-
lation by both GRK2 and GRK5, and these two isozymes
phosphorylate L2-AR on overlapping sites [31]. Our own pre-
liminary data from two-dimensional phosphopeptide maps of
hSPR following in vitro phosphorylation by either GRK2 or
GRK5 show 10 distinct phosphopeptides, most of which are
common to both GRK2 and GRK5 (unpublished observa-
tion). The physiological signi¢cance of these ¢ndings also re-
mains to be evaluated. It should be pointed out that hSPR is
not the only GPCR whose phosphorylation by a GRK occurs
with a high stoichiometry. For example, L2-AR reconstituted
into phospholipid vesicles is phosphorylated by GRK2 to a
stoichiometry of 4 mol phosphate/mol of receptor which in-
creases to 11 mol of phosphate/mol receptor in the presence of
GLQ [32]. Similarly, m2-muscarinic receptor is phosphorylated
by GRK2 to a stoichiometry of 4^5 mol phosphate/mol re-
ceptor, which increases two- to three-fold in the presence of
GLQ [33].
In summary, we provide the ¢rst evidence that GRK5 e⁄-
ciently phosphorylates hSPR in an agonist-dependent manner.
Future studies will determine whether GRK5 plays a role in
the function of hSPR in vivo.
Fig. 4. Kinetic analysis of GRK5-catalyzed phosphorylation of ago-
nist-occupied hSPR in Sf9 membranes. Phosphorylation reactions
were performed in a 50 Wl volume containing approximately 0.5^
25 nM hSPR in urea-washed Sf9 membranes (speci¢c activity:
160 pmol hSPR/mg membrane protein), 3^7 nM GRK5, 1 WM SP,
0.12 mM [32P]Q-ATP (2^3 cpm/fmol), 20 mM Tris^HCl, (pH 7.4),
2 mM EDTA, and 4 mM MgCl2. Incubations were stopped after
3 min at 30‡C by adding 25 Wl SDS sample bu¡er. Receptor phos-
phorylation was visualized by SDS^PAGE/autoradiography. Initial
rates were determined by excising receptor band and counting radio-
activity. Data points represent mean values of three separate experi-
ments performed in duplicate. Data were ¢tted to the Michaelis^
Menten equation using KaleidaGraph1 (Synergy Software, Read-
ing, PA, USA).
FEBS 26177 7-6-02
K. Warabi et al./FEBS Letters 521 (2002) 140^144 143
Acknowledgements: The authors wish to thank Dr. Baowei Chen for
his role in the cloning and expression of human GRK5. This work
was supported by NIH Grants # NS 33405 (to M.M.K.), and 5 T32
AG00024 (M.D.R.). Dr. Kwatra is a senior fellow of the Center for
the Study of Aging and Human Development, Duke University Med-
ical Center.
References
[1] Lefkowitz, R.J. (1998) J. Biol. Chem. 273, 18677^18680.
[2] Bunemann, M., Lee, K.B., Pals-Rylaarsdam, R., Roseberry,
A.G. and Hosey, M.M. (1999) Annu. Rev. Physiol. 61, 169^192.
[3] Zhang, J., Ferguson, S.S.G., Barak, L.S., Aber, M.J., Giros, B.,
Lefkowitz, R.J. and Caron, M.G. (1997) Recept. Channels 5,
193^199.
[4] Pitcher, J.A., Freedman, N.J. and Lefkowitz, R.J. (1998) Annu.
Rev. Biochem. 67, 653^692.
[5] Penn, R.B., Pronin, A. and Benovic, J.L. (2000) Trends Cardio-
vasc. Med. 10, 81^89.
[6] Weiss, E.R., Raman, D., Shirakawa, S., Ducceschi, M.H., Ber-
tram, P.T., Wong, F., Kraft, T.W. and Osawa, S. (1998) Mol.
Vis. 4, 27.
[7] Hisatomi, O., Matsuda, S., Satoh, T., Kotaka, S., Imanishi, Y.
and Tokunaga, F. (1998) FEBS Lett. 424, 159^164.
[8] Premont, R.T., Inglese, J. and Lefkowitz, R.J. (1995) FASEB J.
9, 175^182.
[9] Sallese, M., Iacovelli, L., Cumashi, A., Capobianco, L., Cuomo,
L. and De Blasi, A. (2000) Biochim. Biophys. Acta 2000, 112^
121.
[10] Pronin, A.N. and Benovic, J.L. (1997) J. Biol. Chem. 272, 3806^
3812.
[11] Bouvier, M., Menard, L., Dennis, M. and Marullo, S. (1998)
Curr. Opin. Biotechnol. 9, 522^527.
[12] Nishimura, K., Warabi, K., Roush, E.D., Frederick, J., Schwinn,
D.A. and Kwatra, M.M. (1998) Biochemistry 37, 1192^1198.
[13] Nishimura, K., Frederick, J. and Kwatra, M.M. (1998) J. Recept.
Signal Transduct. Res. 18, 51^65.
[14] Barak, L.S., Warabi, K., Feng, X., Caron, M.G. and Kwatra,
M.M. (1999) J. Biol. Chem. 274, 7565^7569.
[15] Kunapuli, P. and Benovic, J.L. (1993) Proc. Natl. Acad. Sci.
USA 90, 5588^5592.
[16] Kunapuli, P., Onorato, J.J., Hosey, M.M. and Benovic, J.L.
(1994) J. Biol. Chem. 269, 1099^1105.
[17] Pronin, A.N., Satpaev, D.K., Slepak, V.Z. and Benovic, J.L.
(1997) J. Biol. Chem. 272, 18273^18280.
[18] Kwatra, M.M., Schwinn, D.A., Schreurs, J., Blank, J.L., Kim,
C.M., Benovic, J.L., Krause, J.E., Caron, M.G. and Lefkowitz,
R.J. (1993) J. Biol. Chem. 268, 9161^9164.
[19] Premont, R.T., Koch, W.J., Inglese, J. and Lefkowitz, R.J. (1994)
J. Biol. Chem. 269, 6832^6841.
[20] Pei, G., Tiberi, M., Caron, M.G. and Lefkowitz, R.J. (1994)
Proc. Natl. Acad. Sci. USA 91, 3633^3636.
[21] Debburman, S.K., Kunapuli, P., Benovic, J.L. and Hosey, M.M.
(1995) Mol. Pharmacol. 47, 224^233.
[22] Roush, E.D. and Kwatra, M.M. (1998) FEBS Lett. 428, 291^294.
[23] Oppermann, M., Freedman, N.J., Alexander, R.W. and Lefko-
witz, R.J. (1996) J. Biol. Chem. 271, 13266^13272.
[24] Diviani, D., Lattion, A.L., Larbi, N., Kunapuli, P., Pronin, A.,
Benovic, J.L. and Cotecchia, S. (1996) J. Biol. Chem. 271, 5049^
5058.
[25] Rockman, H.A., Choi, D.J., Rahman, N.U., Akhter, S.A., Lef-
kowitz, R.J. and Koch, W.J. (1996) Proc. Natl. Acad. Sci. USA
93, 9954^9959.
[26] Ishizaka, N., Alexander, R.W., Laursen, J.B., Kai, H., Fukui, T.,
Opperman, M., Lefkowitz, R.J., Lyons, P.R. and Griendling,
K.K. (1997) J. Biol. Chem. 272, 32482^32488.
[27] Dale, L.B., Bhattacharya, M., Anborgh, P.H., Murdoch, B.,
Bhatia, M., Nakanishi, S. and Ferguson, S.S.G. (2000) J. Biol.
Chem. 275, 38213^38220.
[28] Berrada, K., Plesnicher, C.L., Luo, X. and Thibonnier, M. (2000)
J. Biol. Chem. 275, 27229^27237.
[29] Tiruppathi, C., Yan, W., Sandoval, R., Naqvi, T., Pronin, A.N.,
Benovic, J.L. and Malik, A.B. (2000) Proc. Natl. Acad. Sci. USA
97, 7440^7445.
[30] Eckhart, A.D., Duncan, S.J., Penn, R.B., Benovic, J.L., Lefko-
witz, R.J. and Koch, W.J. (2000) Circ. Res. 86, 43^50.
[31] Fredericks, Z.L., Pitcher, J.A. and Lefkowitz, R.J. (1996) J. Biol.
Chem. 271, 13796^13803.
[32] Kim, C.M., Dion, S.B. and Benovic, J.L. (1993) J. Biol. Chem.
268, 15412^15418.
[33] Richardson, R.M., Kim, C., Benovic, J.L. and Hosey, M.M.
(1993) J. Biol. Chem. 268, 13650^13656.
FEBS 26177 7-6-02
K. Warabi et al./FEBS Letters 521 (2002) 140^144144
